Publications by the researcher in collaboration with Francisco Carmona de la Torre (11)

2025

  1. COVID-19 Vaccine Booster Dose Fails to Enhance Antibody Response to Omicron Variant in Reinfected Healthcare Workers

    Viruses, Vol. 17, Núm. 1

  2. SAINT: Immunological ancillary study to the clinical trial Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial (SAINT)

    CORA.Repositori de Dades de Recerca

2024

  1. Impact of Repeated Variant Exposures on Cellular and Humoral Immunogenicity Induced by SARS-CoV-2 Vaccines †

    Vaccines, Vol. 12, Núm. 12

2023

  1. Photodynamic nasal SARS-CoV-2 decolonization shortens infectivity and influences specific T-Cell responses

    Frontiers in Cellular and Infection Microbiology, Vol. 13

2022

  1. Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain

    Scientific Reports, Vol. 12, Núm. 1

  2. Neutrophil Extracellular Traps, Local IL-8 Expression, and Cytotoxic T-Lymphocyte Response in the Lungs of Patients With Fatal COVID-19

    Chest, Vol. 162, Núm. 5, pp. 1006-1016

2021

  1. Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A, and G against SARS-CoV-2 antigens

    Journal of Clinical Microbiology, Vol. 59, Núm. 2

  2. Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies

    Translational Research, Vol. 232, pp. 60-74

  3. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

  4. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial

    EClinicalMedicine, Vol. 32

2020

  1. The sars-cov-2 ivermectin navarra-isglobal trial (saint) to evaluate the potential of ivermectin to reduce covid-19 transmission in low risk, non-severe covid-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial

    Trials, Vol. 21, Núm. 1